Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:00:59.753Z.
Consensus retrieved: 2026-10-06T10:16:31.961Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:00:59.753Z.
Quote observation: 2026-10-06T14:00:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6144974dc10feafdeab9fb2faa496306bd94303ba79bd56ccf15562219fd1985
Forward PE Ratio (N/A) = Dated Quote Price ($32.07) / Consensus Forward EPS ($-4.13)
FORWARD PE RATIO
N/A
Celldex Therapeutics, Inc.
Market Cap
$2.13B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | $2.13B | N/A |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 16.02 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.17B | 27.08 |
| Alvotech (ALVO)vs › | $2.07B | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.05B | N/A |
| Azenta, Inc. (AZTA)vs › | $2.04B | 89.23 |
| Inspire Medical Systems, Inc. (INSP)vs › | $2.04B | 59.15 |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $2.03B | N/A |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 16.63 |
| AxoGen, Inc. (AXGN)vs › | $2.01B | 84.45 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $32.07, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-4.13 | $-4.19 – $-3.99 | 8 | n/m |
| 2027-12-31 | $-4.22 | $-4.56 – $-3.67 | 8 | n/m |
| 2028-12-31 | $-3.38 | $-5.16 – $-1.29 | 9 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
